Redesigning what a catheter can see
Howard Rosen runs Evident Vascular, a San Jose medtech company he co-founded to rebuild intravascular ultrasound from the inside out. IVUS is a catheter-based imaging technique that lets interventional physicians look at a blood vessel from within, guiding how they treat disease. Evident's platform folds artificial intelligence into that image - sharpening interpretation and simplifying the workflow around it - and is aimed first at peripheral vascular procedures, then coronary.
The thesis is specific. Legacy IVUS systems, Rosen points out, were built primarily for the heart. Peripheral use came second. But the market moved: peripheral arterial and venous procedures have become the largest and fastest-growing segment for IVUS in the United States. Evident designs for that reality rather than adapting a coronary-first tool to fit it.
There is also a stubborn trade-off Rosen wanted to erase. As he puts it, some companies chase ease of use and others chase image quality, but no single platform managed to deliver both. Refusing to accept that choice is, in a sentence, the founding premise of the company.
Some companies focus on ease of use, and some companies focus on image quality, but no one company could do both.Howard Rosen, on why he started Evident Vascular
The long route to the corner office
Rosen did not parachute in from another industry. He spent 21 years at Boston Scientific, starting as a territory sales manager and working up through the marketing ranks across peripheral vascular and cardiovascular business units. That floor-level start - carrying a bag, learning what physicians actually need in a procedure room - shaped how he builds products decades later.
From Boston Scientific he moved through a series of leadership roles: vice president of sales and marketing at BG Medicine, a Flagship Pioneering company; vice president of the blood collections business unit at Haemonetics; and then the chapter that most defines his reputation as an operator. At Intact Vascular he served as vice president of marketing and business development, then took over as head of the company and integrated it after Royal Philips acquired it in 2020. At the same time he held a marketing and business development role for Vesper Medical, an Intact spinout, which Philips also acquired, in 2022.
Two companies, two acquisitions by the same strategic buyer. It is the kind of track record that lets a founder raise money on a phone call - and it explains why Vensana Capital incubated Evident and led its $35 million Series A when the company came out of stealth in October 2023.
Legacy IVUS platforms were originally designed primarily for coronary procedures and secondarily for peripheral applications.Howard Rosen, on the gap Evident is built to close
Go slow to go fast
Ask Rosen about startup orthodoxy and he pushes back on the most famous line in the playbook. "Fail fast" works when the cost of failure is a rewritten feature. In medical devices, the cost is a patient on a table. His counter-philosophy is blunt: in healthcare you launch right, or you do not launch at all.
In practice that means discipline before speed. Validate the problem and the market before falling in love with a product. Engage the FDA early and often so the regulatory path is de-risked rather than discovered late. And keep the first-generation product ruthlessly scoped. Rosen describes learning to say "no" as a complete sentence - not "no, but," not "yes, we can add that." Every extra capability is a delay, and the answer to most of them is the same: yes, but not in the first generation.
He applies the same patience to who sits around the company. Rosen brought key opinion leaders - the physicians who will actually use the device - into Evident's development before the company even had office space. He treats them as people who shape the mission, not consultants hired to bless a finished plan. Board composition and investor quality, in his view, matter more than a headline valuation.
I started saying no as a complete sentence.Howard Rosen, on protecting a first-generation product
What comes next
In March 2025, Evident closed a Series B. New investors Shangbay Capital and two undisclosed multinational strategics joined founding backer Vensana Capital. The round funds continued development of the next-generation IVUS platform and supports the path toward FDA 510(k) clearance and a U.S. market launch. Rosen framed the raise as a vote of confidence in both the mission and the growing clinical role of intravascular imaging.
Evident today runs with a team of roughly 38 people out of San Jose, alongside co-founders Danielo Piazza, the chief product officer, and Patrick Phillips, the chief technology officer. For Rosen, the ambition is less about a single device than a shift in the category: making AI-guided ultrasound useful and accessible enough that more physicians reach for it, in more procedures, with more confidence in what they see.
- He earned his B.S. in Business Administration from Northeastern University in Boston.
- His career began on the sales floor at Boston Scientific, not in an executive suite.
- He has now helped build three vascular companies - two of which ended up inside Royal Philips.
- He assembled Evident's clinical advisers before the startup had walls to put them behind.